Results 121 to 130 of about 3,972 (148)

A plain language summary of two trials for larotrectinib in people with TRK fusion-positive lung cancer to learn how well the drug works and how safe it is. [PDF]

Future Oncol
Drilon A, Lin JJ, Burcoveanu DI, Ollis C, Reiss M, Torberger O, Moreno V.   +6 more
europepmc   +1 more source

Regulatory Perspectives in Precision Oncology: Challenges and Opportunities for Tyrosine Receptor Kinase (NTRK) Inhibitors in Non-small Cell Lung Cancer (NSCLC). [PDF]

Cureus
Gainor J, Popat S, Bundy L.
europepmc   +1 more source

Redifferentiation Effect of Larotrectinib for <i>NTRK</i> Fusion-Positive Pediatric Thyroid Cancer and Outcomes After Therapy. [PDF]

J Endocr Soc
Castellanos LE, Yedururi S, Waguespack SG.   +2 more
europepmc   +1 more source

Congenital mesoblastic nephroma: a single-center retrospective study. [PDF]

Transl Pediatr
Li J, Yan M, Hu T, Wu L, Zhou C, Zhao Q, Shen Q, Zhou J, He L, Li T, Zhou L.   +10 more
europepmc   +1 more source

TPM3-NTRK1 Fusion Cervical Sarcoma: A Case Report of a Novel Subset of Gynaecological Sarcomas and Successful Treatment of Recurrent Disease With Trk-Inhibition Therapy. [PDF]

Cureus
Lowe-Zinola J, Elghobashy M, Evans M, Hafeez T, El-Ghobashy A.   +4 more
europepmc   +1 more source

Evidence and gaps in tumor-agnostic therapies for breast cancer: a narrative review. [PDF]

Transl Breast Cancer Res
Jones DT, Nanda RK, Dhillon M, Hanspal A, Makhdoom EN, Ta J, Srinivasmurthy R, Hussain AA, Hattin R, Vu T, Myat YM, Aboaid H, Thein KZ.   +12 more
europepmc   +1 more source

Entrectinib attenuates LPS-induced neuroinflammation by inhibiting JNK, p38, and AKT pathways and ameliorates cognitive impairment. [PDF]

Arch Pharm Res
Woo H, Kim SW, Kim S, Chae S, Kim J.
europepmc   +1 more source

Comprehensive characterization and targeted treatment of a pediatric epithelioid glioblastoma with a rare TRIM24-NTRK2 fusion. [PDF]

NPJ Precis Oncol
Keane S, Sjöberg I, Deland L, Lindlöf A, Bontell TO, Kling T, Blomstrand M, Fagman H, Nilsson JA, Nilsson D, Sabel M, Carén H, Abel F.   +12 more
europepmc   +1 more source

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas [PDF]

Cancer, 2023
Background: Larotrectinib, a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor, has demonstrated efficacy in adult and pediatric patients with various solid tumors harboring NTRK gene fusions.
Victor Moreno, Shivaani Kummar, David Hong   +2 more
exaly   +5 more sources